Hong Xiang

Hong Xiang is responsible for Immune-Onc’s Development Sciences functions and activities, including non-clinical and clinical pharmacology, pharmacokinetics, pharmacodynamics, toxicology, bioanalytical sciences and immunogenicity, biomarkers and diagnostics development.

Hong has over 20 years of experience in all phases of drug development at both established and early-stage biotech companies. Most recently, she was a director in the Department of Clinical Pharmacology, Modeling and Simulation at Amgen and was the clinical pharmacology lead for bemarituzumab, a fast-track Phase 3 program in gastric and gastroesophageal junction cancer with multiple clinical studies in other tumor types.

Prior to Amgen, Hong spent over six years at Five Prime Therapeutics as a director/senior director, where she established and led the clinical pharmacology department. She also led clinical biomarkers and clinical diagnostic development before Five Prime was acquired by Amgen and was a member of the clinical leadership team.

Hong started her biotech career at Genentech. During her 16 year tenure, she worked with over 20 oncology molecules as a pharmacology sub-team leader or a team member, co-authored 8 INDs, and supported multiple studies for the development of Genentech’s pipeline molecules including marketed products such as Perjeta®, Lucentis®, and Tarceva®.

Hong received her Ph.D. in Molecular Biology from the University of Missouri-Columbia and completed her post-doctoral fellowship in Neuroscience from the University of Washington. She has authored dozens of peer-reviewed manuscripts.